REFERENCES
- Monzani G, Bergesio F, Ciuti R, Rosati A, Frizzi V, Serruto A. : Lipoprotein abnormalities in chronic renal failure and dialysis patients. Blood Purification 1996; 14: 262–272
- Shoji T, Nishizawa Y, Kawagishi T, et al. Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis. Atherosclerosis 1997; 131: 229–236
- Fiorillo C, Oliviero C, Rizzuti G, Nediani C, Pacini A, Nassi P. Oxidative stress and antioxidant defences in renal patients receiving regular hemodialysis. Clin Chem Lab Med 1998; 36: 149–153
- Paliñski W, Horkko S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. J Clin Invest 1996; 98: 800–814
- Pereira B JG, Shapiro L, King A J, Falagas M E, Strom J A, Dinarello C hA. Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 1994; 45: 890–896
- Pertosa G, Grandallano G, Gesualdo L, Ranieri E, Monno R, Schena P. Interleukin-6 interleukin-8, and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int 1998; 54: 570–579
- Dasgupta A, Hussain S, Ahmad S. Increased lipid peroxidation i patients on maintenance hemodialysis. Nephron 1992; 60: 56–59
- Paul J L, Sall N D, Soni T, et al. Lipid peroxidation abnormalities in hemodialyzed patients. Nephron 1993; 64: 106–109
- Zima T, Haragsim L, Stipek S, Bartova V, Nemecek K. Lipid peroxidation on dialysis membranes. Biochem Mol Biol Int 1993; 29: 531–537
- Niva T. β2-Microglobulin dialysis amyloid and its formation: Role of 3-deoxyglucosone and advanced glycation end products. Nephron 1997; 76: 373–391
- Friedlander M A, Witko-Sarsat V, Nguyen A T, et al. The advanced glycation end-product pentosidine and miocyte activation in uremia. Clin Nephrol 1996; 45: 379–382
- Miyata T, Wada Y, Cai Z, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170–1181
- Witko-Sarsat V, Eriedlander M, Nguyen A T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524–2532
- Turan B, Delilbasi E, Dalay N, Sert S, Afrasyap L, Sayal A. Serum selenium and glutathione peroxidase activities in their interaction with toxic metals in dialysis and renal transplantation patients. Biol Trace Elem Res 1992; 33: 95–102
- Chen C K, Liaw J M, Juang J G, Lin T H. Antioxidant enzymes and trace elements in hemodialyzed patients. Biol Trace Elem Res 1997 1992; 58: 149–157
- Roxborough H E, Mercer C, McMaster D, Maxwell A P, Young I S. Plasma glutathione peroxidase activity is reduced in hemodialysis patients. Nephron 1999; 81: 278–283
- Pertosa G, Gesualdo L, Bottalico D, Schena F P. Endotoxins modulate chronically tumor necrosis factor α and interleukin-6 release by uraemic monocytes. Nephrol Dial Transplant 1995; 10: 328–333
- Gibbons R AS, Martinez O M, Garovoy M R. Altered monocyte function in uremia. Clin Immunol Immunopath 1990; 56: 66–80
- Halma C, Daha M R, Feitsma R IJ, et al. Does hemodialysis impair macrophage Fc receptor function?. Nephrol Dial Transplant 1992; 7: 618–622